Patent ID: RE39197

Claim:
A compound of the formula I: or a pharmaceutically-acceptable salt or pharmaceutically-acceptable prodrug thereof of a compound of formula I , wherein R 1 , R 2 , R 3 , R 4 , and R 5 are independently selected from a. hydrogen, b. halogen, c. alkyl, d. haloalkyl, e. alkoxy, f. cyano, g. nitro, and h. carboxaldehyde, and with the proviso that at least one of R 1 or and R 3 is a “cis-cinnamide” or a “trans-cinnamide”, defined as wherein R 8 and R 9 are each independently selected from a. hydrogen, and b. alkyl, c. carboxy alkyl, d. alkylaminocarbonyl alkyl, and e. dialkylaminocarbonyl alkyl, and R 10 and R 11 are each independently selected from a. hydrogen, b. alkyl, c. cycloalkyl, d. alkoxycarbonylalkyl, e. hydroxyalkyl, and f. heterocyclylalkyl, or where NR 10 R 11 is R 10 and R 11 are taken together with the N to form an unsubstituted heterocyclyl group, or a substituted heterocyclyl, where the substituted heterocyclyl group is substituted by one or more than one substituent, where the substituents are each independently selected from 1) alkyl, 2) alkoxy, 3) alkoxyalkyl, 4) cycloalkyl, 5) aryl, 6) heterocyclyl, 7) heterocyclylcarbonyl, 8) heterocyclylalkylaminocarbonyl, 9) hydroxy, 10) hydroxyalkyl, 11) hydroxyalkoxyalkyl, 12) carboxy, 13) carboxycarbonyl, 14) carboxaldehyde, 15) alkoxycarbonyl, 16) arylalkoxycarbonyl, 17) aminoalkanoyl, 18) carboxamido, 19) alkoxycarbonylalkyl, 20) carboxamidoalkyl, 21) alkanoyl, 22) hydroxyalkanoyl, 23) alkanoyloxy, 24) alkanoylamino, 25) alkanoyloxyalkyl, and 26) alkylsulfonyl, and wherein Ar is an unsubstituted aryl group, an unsubstituted heteroaryl group, a substituted aryl group, or a substituted heteroaryl group, where the substituted aryl group and the substituted heteroaryl group are substituted by one or more than one substituent, where substitutions the substituents are each independently selected from a. hydrogen, b a . halogen, c b . alkyl, d c . aryl, e d . haloalkyl, f e . hydroxy, g f . alkoxy, h g . alkoxycarbonyl, i h . alkoxyalkoxy, j i . hydroxyalkyl, k j . aminoalkyl, l k . alkyl(alkoxycarbonylalkyl)aminoalkyl, m l . unsubstituted heterocyclylalkyl, n m . substituted heterocyclylalkyl, o n . carboxaldehyde, p o . carboxaldehyde hydrazone, q p . carboxamide, r q . alkoxycarbonyl alkyl, s r . hydroxycarbonylalkyl (carboxyalkyl), t s . cyano, u t . amino, v u . heterocyclylalkylamino, and w v . “trans-cinnamide”, or a pharmaceutically-acceptable salt or prodrug thereof. subject to the proviso that when R 3 is a “cis-cinnamide” or a “trans-cinnamide,” as defined above, one or more than one of the following conditions is fulfilled: (A) Ar is an unsubstituted heteroaryl group, a substituted heteroaryl group, or a substituted aryl group wherein when Ar is a pyridyl group, Ar is substituted and Ar is not substituted by only one alkyl group; (B) one or more than one of R 1 , R 2 , R 4 , and R 5 , as defined above, are other than hydrogen; and (C) R 10 and R 11 are taken together with N to form a substituted or unsubstituted heterocyclyl group, as defined above.